April 16, 2015 – ROCHESTER, NY – The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year. Included in this quarter’s release is functionality that lets users create snapshots of past budgets to be used for better negotiations and invoicing, the ability for organizations to create multiple charge masters, and functionality that provides better handling of protocol amendments. When added into the existing functionality of Clinical Conductor, users are afforded the unique opportunity to track and manage their complex and changing research with an unparalleled level of granularity.
With budget snapshots, researchers are able to create multiple versions of a study’s budget within Clinical Conductor. This gives users the ability to utilize historical budgets during negotiations with sponsors and CROs, track budget changes as a study progresses and keep better historical records that can be referenced during a post-study analysis or for future study preparation. With budget snapshots, the clearer financial picture allows organizations to maximize study budget utilization benefits.
The ability to create and manage multiple charge masters within Clinical Conductor allows organizations to manage complex billing requirements for trials that occur at multiple locations or over a long period of time. In the system, users can now reference multiple charge masters for each study, accounting for the location and time-period in which a procedure was conducted. As yearly cost updates are implemented, they are easily incorporated into ongoing studies, yielding greater accuracy in the assessment of the profitability of an individual study or an entire organization. What’s more, multiple charge masters make it easier to differentiate between grant and industry funding.
Clinical Conductor is also fitted with advanced protocol management functionality. Already the leading CTMS vendor in the industry, the added protocol functionality lets users more easily handle protocol amendments, create multiple versions of protocols and tie them directly to specific patients, ensuring subjects receive the correct procedures at all times. Researchers managing both oncology and long-term observational studies also benefit from the ability to manage investigator-initiated protocols more effectively.
“As research becomes more complex, and organizations partner or consolidate, businesses constantly look for ways to overcome the changing hurdles that inevitably occur during the study process, and technology is steadily becoming the solution to these hurdles,” stated Bio- Optronics VP and COO Jeff Markin. “Beyond that, of any other CTMS application, Clinical Conductor continually advances evolves to provide research organizations with flexible trial management functionality that allows them to conduct studies with relative ease in a compliant, profitable manner.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.